Docetaxel as an Alternative to Paclitaxel after Acute Hypersensitivity Reactions

Abstract

OBJECTIVE:

To review the mechanism involved in paclitaxel-induced hypersensitivity reactions and to evaluate the potential use of docetaxel after acute hypersensitivity reactions (HSRs) to paclitaxel.

DATA SOURCES:

Literature identified through a MEDLINE search (1966–September 2000) and through secondary sources.

DATA SYNTHESIS:

HSRs to paclitaxel can be life-threatening. The exact etiology involved in paclitaxel-induced HSRs has not been fully elucidated; the reactions may be due to the Cremophor EL vehicle or to paclitaxel itself. Options for treatment following HSRs are limited. A rechallenge attempt can be made, but is not always successful. Docetaxel, a semisynthetic taxane, may have a role in therapy for patients unable to tolerate paclitaxel therapy. This review examines the etiology of paclitaxel-induced HSRs and the potential role of docetaxel following these acute reactions.

CONCLUSIONS:

Docetaxel may be a viable alternative for patients who experience HSRs to paclitaxel.